metformin

Promising restorative therapy potentially 5 years away

Latest articles

Researchers identify top target for senolytic drugs

Minnesota team determines that senescent immune cells are the most dangerous type of senescent cell, making them key target for senolytic drugs. Cellular senescence is...

Prescribing exercise – the “miracle cure”

EXi targets chronic illness with digital personalised platform for prescribing exercise. British start-up EXi is making waves with its app for prescribing personalised activity programmes....

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Supplement report

Editor's picks

Researchers identify top target for senolytic drugs

Minnesota team determines that senescent immune cells are the most dangerous type of senescent cell, making them key target for senolytic drugs. Cellular senescence is...

Prescribing exercise – the “miracle cure”

EXi targets chronic illness with digital personalised platform for prescribing exercise. British start-up EXi is making waves with its app for prescribing personalised activity programmes....

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...
metformin

Oisín Biotech on targeting senescence and senolytic gene therapy.

 


“The ultimate goal is to eliminate unnecessary suffering. I think that everyone who believes in the mission of longevity is striving towards this. By realizing these therapies, we can start to fundamentally change the way that humans think about aging and disease.”

Henry Garcia, Head of Aging R&D, Oisín Biotechnologies

 


 

Seattle-based Oisín Biotechnologies is creating therapies to combat a variety of age- related diseases. Their breakthrough gene therapy platform clears senescent cells in a highly precise way, with promising preclinical studies already showing significant median lifespan extension in mice. Oisín’s therapy has been shown to efficiently eliminate senescent cells body-wide in multiple animal models and has demonstrated therapeutic benefit in both disease burden and lifespan. Treated mice lived 20% longer even when treatment was started in old age, and after a single treatment, senescent cell removal rates reached as high as 70%. Oisín’s platform is significantly safer and more cost effective than other delivery systems such as viral approaches, and their therapy is reliable and reproducible. Oisín is doing something that would be impossible using traditional pharmaceutical drugs; if human trials are successful and the technology receives regulatory approval, this promising restorative therapy could potentially be available within 5 years.

Oisín’s Technology is a Third Wave Treatment. First Wave treatments for diseases such as cancer involved radiation and chemotherapeutic agents that killed everything they touched. Second Wave treatments focused on antibodies to stimulate immune cells to kill tumours, but did so with harmful side effects. Third Wave treatments, however, can treat disease without damaging healthy cells and causing harmful side effects.

 


 

“Oisín is pursuing a scientifically sound, targeted approach that may have the potential to address the biological underpinnings of some of society’s most devastating age-related diseases.”

Matthew Scholz, Co-founder & CEO, Oisín Biotechnologies

 


 

Software written in DNA

Oisín uses a software program written in DNA that can be programmed to kill senescent or cancer cells; targeted cells are selectively killed while the surrounding cells are unharmed. Oisín kills damaged cells based on their transcriptional activity. Their approach is predicated on the idea that damaged cells “know” that they are damaged – and that this knowledge can be exploited to coax them into killing themselves. Instead of using traditional pharmaceuticals to poison damaged cells, you can programme damaged cells to self-destruct. Programmable self-destruction is an optimal method to treat disease because it does not harm the body with toxic chemicals. Oisín uses a patented Proteo-Lipid Vehicle (PLV) transfection vector to efficiently deliver non-integrating DNA plasmid to cells. Oisín proprietary platform consists of two main components: an untargeted PLV and a highly targeted DNA payload. These unique PLVs are non-toxic at doses up to 10x expected human therapeutic dose in rodents and non-human primates.

 

First Target and Future Pipeline

The team at Oisín chose kidney disease as their first target, with three particular reasons in mind. Firstly, the kidney is a target that they transfect particularly well, with lung and liver also transfecting well. Secondly, the clinical readout for efficacy is easy, non-invasive and specific. Thirdly, there has been little innovation in kidney disease over the past 30 years, which represents an unmet clinical need for innovative technologies like this one. Oisín’s gene therapy technology could treat many diseases and target more than just senescence. The team is also looking at fibrotic diseases, sarcopenia and chemotherapy-induced damage as potential next indications in their pipeline. Their decisions will be informed by the results of clinical trials and will also depend on regulatory guidance, funding and potential pharma partnering. In 2017, Oisín spun out OncoSenX to focus on advancing their technology for oncology applications. OncoSenX targets solid tumours using genetic information to induce apoptosis (cell death) in cancerous cells.

Cell Repair Therapy for Healthy Longevity

Oisín anticipates that senolytic gene therapy for healthy Longevity would involve several treatments. There would be a vigorous initial phase of therapy followed by maintenance dosing. The cell death rate is highly dependent upon the tissue type and dose. It is unknown what percentage of senescent cells will be cleared in humans and how long it will take for them to reach pre-clearance levels. They will learn more about how the treatments translate to humans during human trials.

 


 

“Oisín likes to say we aim at ‘return on mission’ – the mission being curing aging. If we are even partly successful in this effort, it’d be impossible not to do very well by doing good.”

Gary Hudson, Co-founder & Executive Chairman, Oisín Biotechnologies

 


 

Highlights from Oisín’s Mice Studies

In 2019, 41 mice were treated with Oisín’s targeted therapy. The mice were about 2 years old which is equivalent to a 75-80 year old human according to the Jackson laboratory. There was a 20% increase in median survival in mice that received Oisín’s treatment, and so in 2020, Oisín began a much larger study in collaboration with a team in Europe aimed at functional improvements from clearing senescent cells, rather than solely looking at lifespan effects. That study is on-going and is showing very promising results. A direct comparison from mice to humans isn’t perfect because of the kinetics of aging as well as the differences in efficacy when you translate to humans. If you use the Jackson lab conversion in humans a 20% median survival translates to potentially increasing lifespan from 78 to 94 years. This means that if Oisín’s therapy performs in humans the way it performed in mice, it would increase median lifespan in humans by about 15 years. 

1. Increased Lifespan In Naturally-Aged Mice

These studies showed a significant increase in survival during upper middle age. What was remarkable and unprecedented is what happened when they combined their senolytic with their cancer treatments which has a synergistic effect. Scientists are attributing this to the killing of cancer that naturally occurs in middle age. There is considerable overlap in cancer and senescence.

2. Significant Increased Bone Density

One remarkable finding was that age-related bone density loss was effectively prevented in the male mice. These are DEXA scans of femurs in aged mice treated with Oisin’s therapy show increased bone density.

3. Reduction in Solid Tumours

 

A single injection resulted in 90% reduction in solid tumours after 48 hours.

Oisín’s Clinical Approach

 


 

“Our approach is pretty much the exact opposite of the traditional pharmaceutical approach. With our approach, there is no drug, no poison at all – just a little program written in DNA. We’ve effectively taken targeting out of the realm of chemistry and brought it into the realm of information.”

Matthew Scholz, Co-founder & CEO, Oisín Biotechnologies

 


 

Investment

Methuselah Foundation, MFund, Kizoo Technology Ventures, Advani Family Office and SENS Research Foundation have all invested in Oisín. The company has raised over $8 million for both Oisín and OncoSenX and is currently seeking Series A rounds for both Oisín and OncoSenX and has an open Seed equity round that is partially filled. Oisín’s funding will be used for additional preclinical studies prior to an IND for an aging-related disease indication while OncoSenX’s will be used for the Phase 1 and 2 oncology trials in humans.

Future Functional Studies

Oisín has seen that the effects of their therapy are comparable to transgenic mouse studies conducted by the Mayo Clinic and the Buck Institute. The company is now moving to functional studies and disease models in order to create a clinically approved therapy. They are currently working with European collaborators as well as others to develop their kidney disease clinical package and future pipeline indications. 

Images courtesy of Oisín Biotechnologies

2 COMMENTS

Comments are closed.

Margaretta Colangelo
Contributor Margaretta Colangelo is a native San Franciscan with over 30 years of experience working in the software industry in Silicon Valley. She has been at the forefront of emerging technologies throughout her entire career and has a deep and multifaceted understanding of business, science, and technology, and is highly adept at tracking and forecasting innovation in technology.

Margaretta serves on the advisory boards of the AI Precision Health Institute at the University of Hawaii Cancer Center, Ageing Research at King's (ARK-AI) at King's College London, NaNotics, First Longevity, Robots Go Mental, and on the Board of Directors of the Bring Hope Humanitarian Foundation.
metformin

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Related articles

Researchers identify top target for senolytic drugs

Minnesota team determines that senescent immune cells are the most dangerous type of senescent cell, making them key target for senolytic drugs. Cellular senescence is...

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

VitaDAO announces “Longevity Molecule” research project

VitaDAO will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan. VitaDAO, which...

Harnessing the immune system to target cellular senescence

Deciduous Therapeutics aims for clinical trials of immune-activating senotherapeutic by 2023, with metabolic disease and fibrosis among potential indications. Californian start-up Deciduous Therapeutics has emerged...

Building a longevity biotech from scratch

Alchemab exec talks company creation and how antibody therapeutics may play a role in longevity biotech. Last week, we covered Alchemab Therapeutics’ $82 million Series...
Supps report ad middle